Daniel Robert Bensimhon MD
Adult Congenital Heart Disease, Heart Failure & Transplantation
Medical Director, Advanced Heart Failure & Mechanical Circulatory Support Program
Join to view full profile
1200 N Elm StSte 1982Greensboro, NC 27401
Phone+1 336-832-9292
Fax+1 336-851-8427
Dr. Bensimhon is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Main Line Health System/Lankenau Medical CenterResidency, Gastroenterology, 2017 - 2023
Duke University HospitalFellowship, Cardiovascular Disease, 2001 - 2004- Duke University HospitalResidency, Internal Medicine, 1998 - 2001
University of Pittsburgh School of MedicineClass of 1998
Certifications & Licensure
MI State Medical License 2020 - 2029
IL State Medical License 2021 - 2029
ID State Medical License 2022 - 2029
HI State Medical License 2025 - 2028
OH State Medical License 2022 - 2028
MD State Medical License 2025 - 2028
MA State Medical License 2023 - 2028
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
- American Board of Internal Medicine Cardiovascular Disease
- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite (with Beaker), Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
Clinical Trials
Publications & Presentations
PubMed
- 3 citationsFluid Management of Acute Heart Failure With the Reprieve System: The Randomized Controlled FASTR Trial.James E Udelson, Ali Javaheri, Marat Fudim, Kevin Damman, Jan Biegus
JACC. Heart Failure. 2026-08-01 - 1 citationsOutpatient worsening heart failure: innovative decongestion strategies and health equity implications.Rami Halaseh, Grace K Sun, Ankeet S Bhatt, Alex J Chang, Jana Svetlichnaya
Heart Failure Reviews. 2025-09-01 - 9 citationsRandomized Study Comparing a Novel Intranasal Formulation of Bumetanide With Oral and Intravenous Formulations.Andrew P Ambrosy, Daniel Bensimhon, Galina Bernstein, Brian Kolski, Joel Neutel
Circulation. 2025-03-11
Journal Articles
- Use of ReDS Technology to Triage Heart Failure Patients in the Emergency DepartmentDaniel Bensimhon, MD, Journal of Cardiac Failure
Press Mentions
AHA: Bumetanide Nasal Spray Statistically Bioequivalent to Oral BumetanideNovember 26th, 2024- RSQ-777-02: New Nasal Spray Form of Bumetanide as Effective as Oral and IV Forms in Patients Without HF or HF RiskNovember 18th, 2024
- Nasal Spray Version of Common Diuretic Has Potential to Help Treat Heart FailureNovember 18th, 2024
Grant Support
- Duke Summer Training in Academic Research - Advanced Methods Training (STAR - AMT)DUKE UNIVERSITY2026–2031
- INNOVATE (Integrated National Network for Obstetric and Pediatric AdVAncement in Therapeutic Education)DUKE UNIVERSITY2026–2031
- Duke-Utah HEAL KIDS Pain Resource and Data CenterDUKE UNIVERSITY2024–2030
- Duke-Utah HEAL KIDS Pain Resource and Data CenterDUKE UNIVERSITY2024–2030
- National Career Development Program for Researchers in Pediatric Clinical PharmacologyDUKE UNIVERSITY2024–2028
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: